Daewoong Showcases Drug Delivery Platforms

Daewoong Pharmaceutical showcased three innovative drug delivery platform technologies at the PODD 2026 conference in Boston on November 2. The first, CURE, is a long-acting injectable system utilizing biodegradable polymer microparticles to deliver sustained drug release, reducing dosing frequency for patient convenience. Studies demonstrated the technology's efficacy with peptide drugs and highlighted mass-production achievements.

The second platform, CLOPAM, is a microneedle skin patch delivering drugs through tiny needles. The technology showed promising results in absorption studies and blood concentration changes for GLP-1 class drugs treating obesity and diabetes. Daewoong Pharmaceutical also unveiled advancements in precision manufacturing and automated processes, signaling commercialization potential.

A third platform, Thermicra, is a high-concentration formulation system that reduces biopharmaceutical volume and enables subcutaneous administration of antibodies and their drug conjugates. Results from formulation development and body drug absorption studies presented Thermicra as a viable alternative to overcome biopharmaceutical formulation limitations.

Daewoong Pharmaceutical's Formulation Technology Center head, Kim Kwan-young, presented strategies for applying delivery technologies optimized for specific drug characteristics during the event's opening session. The company intends to forge joint development partnerships with global pharmaceutical and biotech firms, focusing on optimizing administration methods and volume based on each partner's candidate materials.

CEO Park Sung-soo emphasized the importance of delivery technologies and drug-specific manufacturing capabilities to maintain competitiveness in the development of new drugs.